Clinical trials: Chronic Cough
Chronic Cough
Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)
The purpose of this study is to evaluate the efficacy and safety of gefapixant in participants with recent onset chronic cough (duration >8 weeks after onset of cough symptoms) for <12 months and a diagnosis of refractory or…
- Trial name
- NCT04193202
- Testing
- Gefapixant
- Where
- 91 sites in United States, Canada and 10 more
- Volunteers
- 419 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Cough
A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough
A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Chronic Cough
- Trial name
- NCT05392192
- Testing
- ADX-629
- Where
- 14 sites in United States
- Volunteers
- 51 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Cough
Phase II Open-Label Pilot Study of V3381 in Chronic Cough
The investigators hypothesise that cough reflex hypersensitivity, demonstrated in chronic cough patients, is due to a phenomenon known as central sensitisation.
- Trial name
- NCT01401673
- Testing
- Indantadol
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Vernalis (R&D) Ltd
Endometriosis Related Pain, Overactive Bladder
Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function
BAY1817080 is currently under clinical development to treat pain related to unexplained chronic cough or chronic cough not affected by a treatment (refractory and/or unexplained chronic cough, RUCC), or a condition where the…
- Conditions
- Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
- Trial name
- NCT04454424
- Testing
- BAY1817080, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Bayer
Persistent Cough in IPF, Chronic Cough
A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF
Idiopathic pulmonary fibrosis (IPF) is a rare, progressive life-threatening disease that is characterized by exertional dyspnea and persistent dry cough.
- Conditions
- Persistent Cough in IPF, Chronic Cough, IPF
- Trial name
- SCENIC (NCT03864328)
- Testing
- RVT-1601
- Where
- 81 sites in United States, Australia and 9 more
- Volunteers
- 108 people
- Sponsor
- Respivant Sciences GmbH
Refractory Chronic Cough
A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)
A randomized, double-blind, placebo-controlled, crossover, dose escalation study to assess the efficacy and tolerability of gefapixant (AF-219; MK-7264) in participants with refractory chronic cough.
- Trial name
- NCT02349425
- Testing
- Gefapixant
- Volunteers
- 59 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pulmonary Disease, Chronic Obstructive
Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath
The study does not involve testing of a drug (no treatment intervention). The study will will use spirometry (breathing tests) in subjects of 40 years of age and older with a history of cigarette smoking with chronic bronchitis…
- Trial name
- NCT00442468
- Testing
- Non-interventional study.
- Where
- 47 sites in United States
- Volunteers
- 1,283 people
- Sponsor
- GlaxoSmithKline
Refractory Chronic Cough
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
The main purpose of this study is to evaluate the effect of NAL ER on 24-hour cough frequency and to assess safety and tolerability of NAL-ER for treatment of refractory chronic cough.
- Trial name
- RIVER (NCT05962151)
- Testing
- NAL ER
- Where
- 14 sites in Canada, United Kingdom
- Volunteers
- 66 people
- Sponsor
- Trevi Therapeutics
Chronic Cough
A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)
The primary objectives of this study are to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period, and to determine the safety and tolerability of gefapixant.
- Trial name
- NCT03449147
- Testing
- Gefapixant 15 mg BID, Gefapixant 45 mg BID
- Where
- 171 sites in United States, Australia and 18 more
- Volunteers
- 1,317 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Obstructive Pulmonary Disease
A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD
The purpose of this study is to determine the effectiveness of XEN-D0501 over placebo in reducing the daytime cough frequency in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT02233686
- Testing
- XEN-D0501
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- Xention Ltd
Chronic Cough
Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)
The purpose of this study is to evaluate the efficacy and safety of gefapixant, in improving symptoms of cough-induced stress urinary incontinence (SUI) in adult female participants with refractory or unexplained chronic cough.
- Trial name
- NCT04193176
- Testing
- Gefapixant
- Where
- 90 sites in United States, Argentina and 10 more
- Volunteers
- 376 people
- Sponsor
- Merck Sharp & Dohme LLC
Refractory Chronic Cough
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
Part 1 will evaluate the safety, tolerability and PK of single doses of three dose levels of NTX-1175 drug substance administered by dry powder inhaler (NOC-110) compared to a single dose reference nebulizer (NOC-100) treatment…
- Trial name
- NCT05628740
- Testing
- 3 mg NOC-100 (via nebulizer), 1 mg NOC-110 (via DPI) [1x 1 mg capsule], 3 mg NOC-110 (via DPI)
- Where
- 3 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Nocion Therapeutics
Chronic Obstructive Pulmonary Disease
Efficacy of DNK333 in Patients With COPD and Cough
This study evaluates the efficacy and safety of two weeks treatment of DNK333 in patients with COPD and cough.
- Trial name
- NCT01287325
- Testing
- DNK333 100 mg twice daily
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 28 people
- Sponsor
- Novartis
Refractory Chronic Cough
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
- Trial name
- CALM-2 (NCT07650084)
- Testing
- BLU-5937
- Where
- 38 sites in China
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
Refractory Chronic Cough
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 2b adaptive dose-finding study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
- Trial name
- SOOTHE (NCT04678206)
- Testing
- BLU-5937
- Where
- 116 sites in United States, Canada and 5 more
- Volunteers
- 310 people
- Sponsor
- Bellus Health Inc. - a GSK company
Cough, Asthma
Validation of the C-mo System - Cough Monitoring
The goal of this clinical study is to validate C-mo System's ability to automatically detect and characterise cough, in patients over 2 years old with cough as a key or refractory symptom.
- Conditions
- Cough, Asthma, Chronic Obstructive Pulmonary Disease, Gastro Esophageal Reflux
- Trial name
- C-mo_01 (NCT05989698)
- Testing
- C-mo System
- Where
- 8 sites in Portugal
- Volunteers
- 300 people
- Sponsor
- Cough Monitoring Medical Solutions
Chronic Cough
A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006)
This is a randomised, double-blind, placebo-controlled, crossover, single centre study of gefapixant (AF-219/MK-7264) in participants with idiopathic or treatment resistant chronic cough designed to evaluate the effectiveness of…
- Trial name
- EPICC (NCT01432730)
- Testing
- Gefapixant
- Volunteers
- 24 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Chronic Idiopathic Cough
A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With Chronic Idiopathic Cough
The purpose of this study is to determine the effectiveness of XEN-D0501 over placebo in reducing the daytime cough frequency in patients with chronic idiopathic cough.
- Trial name
- NCT02233699
- Testing
- XEN-D0501
- Where
- 2 sites in Ireland, United Kingdom
- Volunteers
- 18 people
- Sponsor
- Xention Ltd
Endometriosis Related Pain, Overactive Bladder
Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function
BAY1817080 is currently under clinical development to treat pain related to unexplained chronic cough or chronic cough not affected by a treatment (refractory and/or unexplained chronic cough, RUCC), or a condition where the…
- Conditions
- Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
- Trial name
- NCT04471337
- Testing
- BAY1817080
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bayer
Chronic Cough
Evaluation of S-600918 in Adults With Refractory Chronic Cough
The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared…
- Trial name
- NCT04110054
- Testing
- S-600918
- Where
- 136 sites in United States, Czechia and 4 more
- Volunteers
- 406 people
- Sponsor
- Shionogi